Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Open-label Study to Evaluate the Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapy in Subjects With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT02271945 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02271945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02271945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Open-label Study to Evaluate the Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapy in Subjects With Relapsed or Refractory Aggressive B-cell Lymphomas
Lead sponsor
MedImmune LLC
Phase
Phase 1/2
Overall status
Completed
Start date
December 1, 2014
Completion date
May 24, 2016
Enrollment
10 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory aggressive b-cell lymphomas